Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy
Open Access
- 27 January 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 16 (3) , 389-396
- https://doi.org/10.1093/annonc/mdi085
Abstract
Purpose: The aim of this multicenter trial was to evaluate the role of ovarian suppression in patients with early breast cancer previously treated with local surgery and adjuvant chemotherapy. Patients and methods: Nine hundred and twenty-six premenopausal patients with completely resected breast cancer and either axillary node involvement or histological grade 2 or 3 tumors were randomized after surgery to adjuvant chemotherapy alone (control arm) or adjuvant chemotherapy plus ovarian suppression (ovarian suppression arm). Ovarian suppression was obtained by either radiation-induced ovarian ablation or triptorelin for 3 years. The analyses were performed with Cox models stratified by center. Results: Median follow-up was 9.5 years. Mean age was 43 years. Ninety per cent of patients had histologically proven positive axillary nodes, 63% positive hormonal receptors and 77% had received an anthracycline-based chemotherapy regimen. Ovarian suppression was by radiation-induced ovarian ablation (45% of patients) or with triptorelin (48%). At the time of randomization, all patients had regular menses or their follicle-stimulating hormone and estradiol levels indicated a premenopausal status. The 10-year disease-free survival rates were 49% [95% confidence interval (CI) 44% to 54%] in both arms (P=0.51). The 10-year overall survival rates were 66% (95% CI 61% to 70%) for the ovarian suppression arm and 68% (95% CI 63% to 73%) for the control arm (P=0.19). There were no variations in the treatment effect according to age, hormonal receptor status or ovarian suppression modality. However, in patients P=0.01). Conclusions: The results of this trial, after at least 10 years of follow-up, do not favor the use of ovarian suppression after adjuvant chemotherapy. The potential beneficial effect in younger women with hormono-dependent tumors should be further assessed.Keywords
This publication has 23 references indexed in Scilit:
- Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI Journal of the National Cancer Institute, 2003
- Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized StudyJournal of Clinical Oncology, 2003
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Menopause and the Risk of Coronary Heart Disease in WomenNew England Journal of Medicine, 1987
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976
- La Castration Dans Le Cancer Du Sein : Chirurgie Ou RadiationsActa Radiologica, 1967
- Clinical trials in malignant diseaseJournal of the Faculty of Radiologists, 1959
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896